Callos Andrew 4

What Happened

• Andrew Callos, EVP & Chief Commercial Officer of Cytokinetics (CYTK), exercised options and immediately sold 11,333 shares on 2026-05-05. The exercise recorded 11,333 shares acquired at $39.13 per share (cost $443,460), and the open-market sale of 11,333 shares at $77.25 per share generated $875,474 in gross proceeds. The filing also shows a derivative disposition of 11,333 shares at $0.00.

Key Details

• Transaction date: 2026-05-05
• Option exercise (code M): 11,333 shares acquired @ $39.13 — $443,460
• Sale (code S): 11,333 shares sold @ $77.25 — $875,474
• Derivative disposition shown: 11,333 shares @ $0.00 (reported as disposed)
• Net difference between sale proceeds and exercise cost: ~$432,014 (gross, before taxes and fees)
• Shares owned after transaction: Not specified in this Form 4
• Timeliness: Filing date and report period are 2026-05-05; not marked as late

Context

• This appears to be a cashless exercise (options exercised and shares sold same day), a common way for insiders to realize gains from option exercises. The zero-dollar derivative disposition line on the form often reflects share surrender for tax withholding or similar mechanics, but the filing does not state the exact reason. As with most insider sales, this is a factual report of a transaction and should not be read as a direct signal of company performance.